Carret Asset Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.52M Sell
41,555
-2,850
-6% -$166K 0.25% 85
2025
Q4
$2.4M Sell
44,405
-6,990
-14% -$336K 0.23% 87
2025
Q3
$2.32M Buy
51,395
+2,288
+5% +$107K 0.23% 92
2025
Q2
$2.27M Sell
49,107
-1,580
-3% -$77.6K 0.24% 88
2025
Q1
$3.09M Buy
50,687
+771
+2% +$44.9K 0.35% 72
2024
Q4
$2.82M Sell
49,916
-3,951
-7% -$221K 0.31% 76
2024
Q3
$2.79M Sell
53,867
-1,880
-3% -$88.2K 0.3% 81
2024
Q2
$2.32M Sell
55,747
-870
-2% -$38.9K 0.27% 88
2024
Q1
$3.07M Sell
56,617
-720
-1% -$36.7K 0.36% 78
2023
Q4
$2.94M Sell
57,337
-506
-0.9% -$26.6K 0.37% 75
2023
Q3
$3.36M Buy
57,843
+85
+0.1% +$5.21K 0.47% 61
2023
Q2
$3.69M Sell
57,758
-1,342
-2% -$90K 0.49% 58
2023
Q1
$4.1M Sell
59,100
-8,843
-13% -$624K 0.57% 51
2022
Q4
$4.89M Buy
67,943
+975
+1% +$73.5K 0.68% 41
2022
Q3
$4.76M Sell
66,968
-600
-0.9% -$43.5K 0.71% 38
2022
Q2
$5.2M Sell
67,568
-164
-0.2% -$12.5K 0.72% 41
2022
Q1
$4.95M Buy
67,732
+385
+0.6% +$25.9K 0.57% 54
2021
Q4
$4.2M Buy
67,347
+2,450
+4% +$144K 0.46% 62
2021
Q3
$3.84M Sell
64,897
-6,450
-9% -$425K 0.46% 64
2021
Q2
$4.77M Buy
71,347
+698
+1% +$45.5K 0.56% 57
2021
Q1
$4.46M Buy
70,649
+1,550
+2% +$96.4K 0.55% 58
2020
Q4
$4.29M Buy
69,099
+1,150
+2% +$70.7K 0.58% 57
2020
Q3
$4.1M Buy
67,949
+8,900
+15% +$536K 0.62% 51
2020
Q2
$3.47M Buy
59,049
+8,525
+17% +$510K 0.56% 58
2020
Q1
$2.82M Buy
50,524
+11,494
+29% +$703K 0.54% 56
2019
Q4
$2.5M Buy
39,030
+7,990
+26% +$458K 0.37% 77
2019
Q3
$1.57M Sell
31,040
-3,004
-9% -$141K 0.25% 94
2019
Q2
$1.54M Sell
34,044
-1,858
-5% -$86.5K 0.25% 93
2019
Q1
$1.71M Sell
35,902
-100
-0.3% -$4.98K 0.28% 88
2018
Q4
$1.87M Sell
36,002
-200
-0.6% -$10.7K 0.34% 77
2018
Q3
$2.25M Sell
36,202
-2,300
-6% -$136K 0.35% 77
2018
Q2
$2.13M Sell
38,502
-2,700
-7% -$146K 0.35% 81
2018
Q1
$2.61M Buy
41,202
+200
+0.5% +$12.9K 0.43% 76
2017
Q4
$2.51M Hold
41,002
0.39% 75
2017
Q3
$2.61M Sell
41,002
-340
-0.8% -$19.9K 0.42% 66
2017
Q2
$2.3M Sell
41,342
-700
-2% -$38.1K 0.39% 73
2017
Q1
$2.29M Sell
42,042
-900
-2% -$49.4K 0.41% 72
2016
Q4
$2.51M Buy
42,942
+3,442
+9% +$188K 0.48% 62
2016
Q3
$2.13M Hold
39,500
0.4% 69
2016
Q2
$2.9M Buy
39,500
+193
+0.5% +$13.6K 0.56% 56
2016
Q1
$2.51M Sell
39,307
-40
-0.1% -$2.52K 0.53% 60
2015
Q4
$2.71M Sell
39,347
-50
-0.1% -$3.3K 0.58% 54
2015
Q3
$2.33M Sell
39,397
-274
-0.7% -$17.4K 0.51% 62
2015
Q2
$2.64M Sell
39,671
-820
-2% -$54K 0.52% 59
2015
Q1
$2.61M Sell
40,491
-250
-0.6% -$15.7K 0.51% 58
2014
Q4
$2.4M Sell
40,741
-300
-0.7% -$16.9K 0.46% 62
2014
Q3
$2.1M Sell
41,041
-1,596
-4% -$79.7K 0.41% 74
2014
Q2
$2.07M Sell
42,637
-2,137
-5% -$105K 0.4% 75
2014
Q1
$2.33M Sell
44,774
-615
-1% -$32.7K 0.46% 66
2013
Q4
$2.41M Sell
45,389
-400
-0.9% -$20.4K 0.49% 58
2013
Q3
$2.12M Sell
45,789
-1,388
-3% -$60.9K 0.47% 60
2013
Q2
$2.11M Buy
+47,177
New +$2.05M 0.44% 59

Other funds holding BMY

Carret Asset Management's BMY Position: Q1 2026 in Review

Carret Asset Management reduced its Bristol-Myers Squibb (BMY) stake by 6.4% in Q1 2026, selling an estimated $166K and leaving 41,555 shares worth $2.52M. The position accounts for 0.25% of the portfolio, ranked #85.

Carret Asset Management first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $5.2M in Q2 2022. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Carret Asset Management held 41,555 shares of Bristol-Myers Squibb worth $2.52M as of Q1 2026.
  • Carret Asset Management sold 2,850 Bristol-Myers Squibb shares in Q1 2026, an estimated $166K.
  • Bristol-Myers Squibb made up 0.25% of Carret Asset Management's portfolio in Q1 2026, its #85 holding.
  • Carret Asset Management first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • Carret Asset Management's Bristol-Myers Squibb position peaked at $5.2M in Q2 2022.
  • 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Carret Asset Management's 13F filing for Q1 2026, filed 15 May 2026.